09Aug 2023
Efficacy of single-dose oral secnidazole for the treatment of trichomoniasis in women co-infected with trichomoniasis and bacterial vaginosis: a post hoc subgroup analysis of phase 3 clinical trial data

Efficacy of single-dose oral secnidazole for the treatment of trichomoniasis in women co-infected with trichomoniasis and bacterial vaginosis: a post hoc subgroup analysis of phase 3 clinical trial data

A study finds that single-dose oral secnidazole 2 g effectively treats trichomoniasis in women with co-existing bacterial vaginosis (BV). BV and trichomoniasis are common causes of vaginitis, linked to higher HIV and STI risks and reproductive issues. The analysis, based on a phase 3 study in the USA, shows 97.7% cure rate for trichomoniasis using secnidazole, compared to 0% with placebo. Secnidazole is FDA-approved for BV and trichomoniasis treatment in both genders, highlighting its significance in addressing co-infections for reduced transmission. Effective co-infection treatments are crucial for public health and reproductive well-being.

  • #gynaecology - ivf

Like

Save

Share